Ruchika Gangwar1, Anil Mandhani, Rama Devi Mittal. 1. Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Abstract
PURPOSE: To investigate the association between two Xeroderma pigmentosum group C polymorphism (XPC Lys939Gln and insertion/deletion PAT -/+ in intron 9) and bladder cancer (BC) susceptibility. MATERIALS AND METHODS: Genotyping was performed in 208 BC patients and 245 controls by PCR-RFLP method. RESULTS: XPC PAT +/+ genotype was associated with elevated risk of BC (p = 0.021, OR = 2.49). XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (p = 0.041, OR = 2.52). Haplotype analysis revealed that variant genotypes C of XPC Lys939Gln and + of PAT, C+ were significantly associated with risk of BC (p = 0.004, OR = 1.70). The CC genotype of Lys939Gln was associated with high risk for recurrence in BCG-treated patients (HR = 3.21, p = 0.036) thus, showing reduced recurrence-free survival (AC + CC/AA = 36/60 months; log rank p = 0.045). CONCLUSION: Polymorphisms and haplotypes in XPC appear to influence susceptibility to BC risk. The variant C allele at Lys939Gln may be responsible for early recurrence in BCG-treated patients.
PURPOSE: To investigate the association between two Xeroderma pigmentosum group C polymorphism (XPC Lys939Gln and insertion/deletion PAT -/+ in intron 9) and bladder cancer (BC) susceptibility. MATERIALS AND METHODS: Genotyping was performed in 208 BC patients and 245 controls by PCR-RFLP method. RESULTS:XPC PAT +/+ genotype was associated with elevated risk of BC (p = 0.021, OR = 2.49). XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (p = 0.041, OR = 2.52). Haplotype analysis revealed that variant genotypes C of XPC Lys939Gln and + of PAT, C+ were significantly associated with risk of BC (p = 0.004, OR = 1.70). The CC genotype of Lys939Gln was associated with high risk for recurrence in BCG-treated patients (HR = 3.21, p = 0.036) thus, showing reduced recurrence-free survival (AC + CC/AA = 36/60 months; log rank p = 0.045). CONCLUSION: Polymorphisms and haplotypes in XPC appear to influence susceptibility to BC risk. The variant C allele at Lys939Gln may be responsible for early recurrence in BCG-treated patients.
Authors: Yawei Qiao; Margaret R Spitz; Zhaozheng Guo; Mohammad Hadeyati; Lawrence Grossman; Kenneth H Kraemer; Qingyi Wei Journal: Mutat Res Date: 2002-11-30 Impact factor: 2.433
Authors: Alan G Casson; Zuoyu Zheng; Susan C Evans; Paul J Veugelers; Geoffrey A Porter; Duane L Guernsey Journal: Carcinogenesis Date: 2005-05-05 Impact factor: 4.944
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: M Felicitas López-Cima; Patricia González-Arriaga; Laura García-Castro; Teresa Pascual; Manuel G Marrón; Xose S Puente; Adonina Tardón Journal: BMC Cancer Date: 2007-08-16 Impact factor: 4.430
Authors: Yi Zhi; Jing Yu; Yang Liu; Quanfang Wei; Fang Yuan; Xiaozhou Zhou; Bo Song; Zhiwen Chen; Jin Yang Journal: Int J Med Sci Date: 2012-08-17 Impact factor: 3.738